I am not knowledgeable enough to know what this means, I was...

I am not knowledgeable enough to know what this means, I was wondering if someone could interpret in layman's terms.  Prima facie it seems to suggest that DEBDOX is a superior treatment than SIRT in all cases of unresectable HCC. But I bet there are lots of nuances here which I am not picking up.

Here is the link to the abstract, and for convenience I have cut and pasted the summary below.

Background/Aim: Hepatocellular cancer is a rising dilemma. Patients with unresectable disease may benefit from locoregional therapy. The comparative effectiveness of radioembolization and Doxorubicin-Drug-Eluting-Beads (DEBDOX) has not been established to date. We compared the performance of radioembolization and DEBDOX in the treatment of hepatocellular carcinoma. Patients and Methods: An analysis of our prospectively managed locoregional therapy (LRT) database was performed. Three hundred and fifty-eight patients were treated with LRT for unresectable HCC, out of which 291 were treated with DEBDOX and 67 with Ytrrium-90 (⁹⁰Y). Comparative toxicity, tumor response, progression-free survival (PFS) and overall survival (OS) were assessed. Propensity score matching was used to reduce treatment-selection bias, producing 48 pairs. Comparative analysis was repeated after propensity matching. Results: Median age was 67 and 65 years for the DEBDOX and ⁹⁰Y groups respectively (p=0.2). Overall survival favored the DEBDOX group (DEBDOX: 15-months, ⁹⁰Y: 6-months, p<0.0001). PFS also favored the DEBDOX group (DEBDOX: 15-months, ⁹⁰Y: 6-months, p<0.0001). All-grade adverse events were similar in both groups, although slightly favoring the DEBDOX group (DEBDOX 10%, ⁹⁰Y 15%, p=0.1). After propensity score matching, again longer OS was seen with the DEBDOX group (DEBDOX 13 months, ⁹⁰Y 4 months; p=0.0077). There were also similar all-grade adverse events that slightly favored DEBDOX (DEBDOX 14%, ⁹⁰Y 20%, p=0.3). Disease control rate was found to be statistically significant, favoring the DEBDOX group (DEBDOX 72%, ⁹⁰Y 48%; p=0.02). Conclusion: Our observation suggests that DEBDOX outperforms ⁹⁰Y with superior efficacy and survival with a trend towards lower all-grade toxicity